The 3rd U-PGx Personalized Medicine Day in Toulouse was successfully organized and completed on 17th November 2017 with the theme ”Pharmacogenomics in Oncology: Deciphering the Ethical, Legal and Societal Issues”. Continue reading
The tyrosine kinase inhibitor sunitinib is used as first-line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed-dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in response. Therefore, dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) models may be useful to optimize treatment. Continue reading
The 3rd UPGx Personalized Medicine Day will be organized in Toulouse, France. The meeting will be co-organized by the Golden Helix Foundation and the University of Toulouse, both partners of the Ubiquitous Pharmacogenomics (UPGx) project, funded by the European Commission (H2020-668353). Continue reading
On July 21st, 2017, H.E. the United States Ambassador to Greece Mr. Geoffrey Pyatt visited the Laboratory of Molecular Biology and Immunology, University of Patras (UPAT), as part of his visit to academic entities in Patras that produce and offer innovative results and services in the biotechnology and healthcare sectors.
The 2nd UPGx Personalized Medicine Day will be organized in Vienna, Austria on Friday May 12th, 2017. The meeting will be organized at the Medical University of Vienna and will follow the 2nd Consortium Meeting of the UPGx project that will be held May 10-11, 2017. Continue reading
Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programmes have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Continue reading